Tumor necrosis factor-alpha antagonism with etanercept improves endothelial progenitor cell counts in patients with psoriasis: etanercept, vascular function and endothelial progenitor cells in psoriasis

Int J Cardiol. 2015 Mar 1:182:387-9. doi: 10.1016/j.ijcard.2014.12.093. Epub 2014 Dec 27.
No abstract available

Keywords: Arterial stiffness; Endothelial progenitor cells; Etanercept; Flow-mediated dilation; Psoriasis; TNF-alpha.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cell Count
  • Endothelial Progenitor Cells / cytology*
  • Endothelial Progenitor Cells / drug effects
  • Etanercept / therapeutic use*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Psoriasis / physiopathology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Vascular Stiffness / drug effects*
  • Vasodilation / drug effects*
  • Vasodilation / physiology

Substances

  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Etanercept